15 citations
,
June 2019 in “Journal of Neuroendocrinology” This study found that isoallopregnanolone reduced stress-induced tic-like behaviors and sensorimotor gating deficits in a mouse model of Tourette syndrome, suggesting potential therapeutic properties comparable to existing treatments like haloperidol and finasteride.
24 citations
,
June 2013 in “Journal of neuroendocrinology” This research observed that 5α-reductase inhibitors showed significant tic-suppressing effects in Tourette's syndrome, suggesting a key role for this enzyme in the disorder's pathogenesis.
January 2022 in “International review of movement disorders” In this review, the authors found that cannabinoids and steroid-related drugs show potential for treating Tourette syndrome, but existing evidence is limited and further research is needed to confirm their efficacy and safety.
24 citations
,
July 2016 in “Revue Neurologique” This review discusses treatment options for tics in Gilles de la Tourette syndrome, highlighting existing therapies and potential future advancements, but reports no new clinical findings.
42 citations
,
December 2007 in “American Journal of Psychiatry” This study examined finasteride, a 5-alpha-reductase inhibitor, for treating a Tourette’s syndrome patient unresponsive to traditional therapy, noting its limited side effects.